In this video, health-care analyst David Williamson takes a closer look at Pfizer's first-quarter results and guidance reduction. Diving past the headlines, investors need to look to the future when valuing the potential of this Big Pharma.
Watch and get a succinct breakdown of the first quarter and find out what critical catalysts are coming for Pfizer investors in the near future.
Editor's note: Xeljanz has not been officially rejected in Europe, but it did recently receive a negative opinion from the European Medicines Agency.
